• 1
    Palella FJJr, Delaney KKM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338: 853-860.
  • 2
    Centers for Disease Control. HIV prevalence estimates—United States, 2006. MMWR Morb Mortal Wkly Rep. 2008; 57: 1073-1076.
  • 3
    Palella FJJr, Baker RK, Moorman AC, et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr. 2006; 43: 27-34.
  • 4
    Silverberg M, Lau B, D'souza G, et al. Trends in cumulative incidence of cancer among HIV-infected patients in North America [abstract]. Paper presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010); February 16-19, 2010; San Francisco, Calif. Abstract 758.
  • 5
    Engels EA, Pfeiffer RM, Goedert JJ, et al; for the HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006; 20: 1645-1654.
  • 6
    Bonnet F, Burty C, Lewden C, et al; Agence National de Recherses dur le Sida et les Hepatities Virales EN19 Mortalite Study Group; Mortavic Study Group. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009; 48: 633-639.
  • 7
    Monforte A, Abrams D, Pradier C, et al; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008; 22: 2143-2153.
  • 8
    Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009; 52: 611-622.
  • 9
    Patel P, Hanson DL, Sullivan PS, et al; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008; 148: 728-736.
  • 10
    Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007; 45: 103-110.
  • 11
    Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006; 24: 1383-1388.
  • 12
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370: 59-67.
  • 13
    Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D; Clinical Epidemiology Group of the FHDH-ANRS CO4 Cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009; 10: 1152-1159.
  • 14
    Prosperi MCF, Cozzi-Lepri A, Castagna A, et al; Icona Foundation Study Group. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis. 2010; 50: 1316-1321.
  • 15
    Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006; 43: 47-55.
  • 16
    Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007; 21: 1957-1963.
  • 17
    Sridhar KS, Flores MR, Raub WAJr, Saldana M. Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. Chest. 1992; 102: 1704-1708.
  • 18
    Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer. 1996; 15: 325-339.
  • 19
    Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. Cancer. 2000; 88: 563-569.
  • 20
    Alshafie MT, Donaldson B, Oluwole SF. Human immunodeficiency virus and lung cancer. Br J Surg. 1997; 84: 1068-1071.
  • 21
    Spano J-P, Massiani MA, Bentata M, et al. Lung cancer in patients with HIV infection and review of the literature. Med Oncol. 2004; 21: 109-115.
  • 22
    Lavole A, Chouaid C, Baudrin L, et al. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer. 2009; 65: 345-350.
  • 23
    Bertolaccini L, Lyberis P, Soncini S, Di Perri G, Manno E. Clinical characteristic lung cancer in HIV-infected patients. Cancer Therapy. 2008; 6: 903-906.
  • 24
    Clifford GM, Polesel J, Rickenbach M, et al; Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005; 97: 425-432.
  • 25
    Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003; 32: 527-533.
  • 26
    Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009; 52: 203-208.
  • 27
    Tenholder MF, Jackson HD. Bronchogenic carcinoma in patients seropositive for human immunodeficiency virus. Chest. 1993; 104: 1049-1053.
  • 28
    Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS. 2007; 21: 207-213.
  • 29
    Marshall M, McCormack M, Kirk G. Effect of cigarette smoking on HIV acquisition, progression, and mortality. AIDS Educ Prev. 2009; 21( 3 suppl): 28-39.
  • 30
    International Early Lung Cancer Action Program Investigators, Henschke CI, Yip R, Miettien OS. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA. 2006; 296: 180-184.
  • 31
    Henschke CI, Miettinen OS. Women's susceptibility to tobacco carcinogens. Lung Cancer. 2004; 43: 1-5.
  • 32
    Risch HA, Howe GR, Jain M, Burch JD, Holowaty JE, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol. 1993; 138: 281-293.
  • 33
    Harris RE, Zang EA, Anderson JI, Wynder EL. Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol. 1993; 22: 592-599.
  • 34
    Marquez-Garban DC, Chen HW, Fishebein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 2007; 72: 135-143.
  • 35
    Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 2006; 24: 59-63.
  • 36
    Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the Vitamins and Lifestyle Study. J Clin Oncol. 2010; 28: 1540-1546.
  • 37
    Levine AM, Seaberg EC, Hessol NA, et al. HIV as a risk factor for lung cancer in women: data from the Women's Interagency HIV Study. J Clin Oncol. 2010; 28: 1514-1519.
  • 38
    Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
  • 39
    Scagliotti GV, Parikh P, von Powel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
  • 40
    Lewden C, May T, Rosenthal E, et al; ANRS EN19 Mortalite Study Group and Mortavic 1. Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic) J Acquir Immune Defic Syndr. 2008; 48: 590-598.